Oral squamous cell carcinoma (OSCC)

This phase 3 trial tests whether adding sintilimab, an immunotherapy drug, to chemotherapy before surgery helps people with early-stage oral squamous cell carcinoma. Participants are adults aged 18 to 75 with cT2N0M0 oral cancer that can be removed by surgery. Half receive sintil…

Researchers are testing whether adding rimegepant to standard chemoimmunotherapy before surgery helps shrink oral or oropharyngeal squamous cell carcinoma more effectively. The trial enrolls adults with primary or recurrent disease who are scheduled for surgery. Participants rece…

This phase II trial is testing whether combining a TROP-2 antibody-drug conjugate (sacituzumab govitecan or sacituzumab tirumotecan) with the immunotherapy drug toripalimab can shrink tumors in people with resectable, locally advanced oral squamous cell carcinoma. Participants re…

This study tests whether giving the immunotherapy drug nivolumab before surgery can shrink tumors in people with advanced oral cancer. About 60 adults with resectable oral squamous cell carcinoma will receive nivolumab, then have surgery. Researchers will also look for biomarkers…

This study tests whether rinsing with hydrogen water can reduce mouth inflammation and pain in people recovering from oral cancer surgery that used a free flap reconstruction. Thirty-six participants will use hydrogen water or plain water for oral care over 7 days. Researchers wi…

This study aims to find biological markers in saliva, mouth rinse, blood, or tissue that could help identify and predict the course of oral cancer, gum disease, and tooth decay. Researchers will collect health information and samples from 4,000 adults with these conditions and he…

This study investigates whether substances in saliva, specifically interleukin-6 levels and certain gene variations, can indicate whether oral cancer has spread to lymph nodes in the neck. Researchers will collect saliva samples from adults with oral squamous cell carcinoma befor…